First global approval
When to seek help red flags: Contact your GP or trial clinician promptly if you experience persistent or worsening nausea and vomiting, are unable to keep fluids down for more than 24 hours, or notice significant unintentional weight loss or difficulty maintaining adequate nutrition
Notably, only one registered clinical study exists to date, which evaluates an implant-based delivery system of Exenatide and is currently in Phase 1 with an Active, not recruiting status (NCT05670379), initiated on December 20, 2024, and expected to conclude by August 2025
Shapely FAQs We navigate insurance on your behalf and are able to work with the vast majority of insurance companies to get cost-effective access to GLP-1 medications like Mounjaro and Wegovy
Some start with microdosing to change their habits, while others stick with small doses long-term as part of a bigger health plan
So we tested it ourselves